ClinicalTrials.gg

Program

CPO-107

Also written as “CPO107”, “JMT601 Injection” and “JMT601”.

Its studies are mostly in Lymphoma, Non-Hodgkin · Glomerulonephritis, Membranous · Lymphoma, B-Cell, led by 2 companies.

Furthest: phase 2, since Jun 11, 20253 company-led studies, 2 open or runningNext primary completion: Apr 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group22 open or runningphase 2since Jun 11, 2025Jul 19, 2023Apr 1, 2027phase 2 · NCT07029139
Conjupro Biotherapeutics10 open or runningphase 1since Mar 2, 2021Mar 2, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 2, 2021First study: phase 1 study in Lymphoma, Non-HodgkinNew to Conjupro BiotherapeuticsConjupro Biotherapeutics · NCT04853329 · 7 enrolled · United States
  2. Jul 19, 2023CSPC Pharmaceutical Group's first study: phase 1 study in Lymphoma, B-CellNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06725524 · 186 planned · China
  3. Jun 11, 2025Phase 2 study in Primary Membranous NephropathyCSPC Pharmaceutical Group · NCT07029139 · 156 planned

Ahead

  1. Apr 1, 2027Primary completion: phase 2 study in Primary Membranous NephropathyCSPC Pharmaceutical Group · NCT07029139

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07029139Primary Membranous Nephropathy2Not yet recruitingCSPC Pharmaceutical GroupApr 1, 2027156
NCT06725524Lymphoma, B-Cell · China1RecruitingCSPC Pharmaceutical GroupDec 31, 2025186
NCT04853329Lymphoma, Non-Hodgkin · United States1TerminatedConjupro BiotherapeuticsJan 31, 20237

How it is read

Names in the registry

  • “CPO107”, 1 entry
  • “JMT601 Injection”, 1 entry
  • “JMT601”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.